Mitochondrial cardiomyopathies are a heterogeneous group of primary or syndromic cardiomyopathies in which structural and functional myocardial damage results from impaired mitochondrial function, particularly oxidative phosphorylation, adenosine triphosphate (ATP) production, redox homeostasis, mitochondrial lipid metabolism, mitochondrial fusion and fission dynamics, or organelle biogenesis. The heart is one of the most vulnerable organs because it depends largely on oxidative metabolism to maintain contraction, relaxation, electrical conduction and ionic homeostasis. When energy availability is reduced or becomes inefficient, the cardiomyocyte may respond with hypertrophy, dilation, systolic dysfunction, diastolic dysfunction, conduction abnormalities, arrhythmias, fibrosis and heart failure.
The term does not identify a single disease. It may indicate a cardiomyopathy caused by variants of mitochondrial deoxyribonucleic acid (mtDNA), by variants of nuclear deoxyribonucleic acid (DNA) encoding mitochondrial proteins, by multiple mtDNA deletions, by defects in mitochondrial genome maintenance, by multisystemic syndromes such as MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), MERRF (myoclonic epilepsy with ragged-red fibers), Kearns-Sayre syndrome, Leigh syndrome, Barth syndrome or respiratory chain defects. Cardiac expression may be isolated, but more often it is part of a disease involving the nervous system, skeletal muscle, eye, inner ear, kidney, liver, endocrine system, gastrointestinal tract and systemic metabolism.
Epidemiology is difficult to define because mitochondrial diseases are rare, genetically complex, often underdiagnosed and clinically highly variable. The most frequently cited estimates indicate that primary mitochondrial diseases overall have a prevalence at least in the order of 1 case per 5,000 births or adults, while cardiac involvement varies according to genotype, age, screening method and the definition used. Studies on genetically confirmed adult cohorts have documented cardiomyopathy, conduction defects, arrhythmias and risk of major cardiac events. In pediatric forms, cardiac involvement may be early and severe; in adults, it may emerge as left ventricular hypertrophy, dilated cardiomyopathy, conduction blocks, arrhythmias or progressive heart failure. The key clinical point is that prognosis does not depend only on ejection fraction, but on the combination of genotype, mutational load, heteroplasmy, extracardiac involvement, arrhythmias, fibrosis, renal function, nutritional status and vulnerability to metabolic crises.
Mitochondrial cardiomyopathies arise from genetic or, more rarely, acquired defects that impair mitochondrial energy production or the structural stability of the organelle. Genetic causes are divided into two broad categories: mtDNA variants and variants in nuclear genes encoding proteins required for the respiratory chain, assembly of oxidative complexes, mtDNA replication, mitochondrial translation, mitochondrial dynamics, cardiolipin metabolism or mitochondrial quality control. This distinction is clinically essential because mtDNA variants follow maternal transmission and are influenced by heteroplasmy and tissue threshold, whereas nuclear variants may follow autosomal dominant, autosomal recessive or X-linked inheritance.
In mtDNA-related diseases, a cell may contain a mixture of normal mitochondria and mutated mitochondria. This condition is called heteroplasmy. Clinical expression depends on the proportion of mutated mitochondrial genome, its distribution across different tissues, the energy requirement of the organ and the threshold beyond which the tissue can no longer compensate. The heart may be affected even when other districts appear less compromised, because the continuous demand for ATP makes the myocardium poorly tolerant of reduced oxidative phosphorylation. Moreover, the mutational load measured in blood may not accurately reflect that of the myocardium, skeletal muscle or other tissues, especially in adulthood, because the proportion of mutated mtDNA may vary over time and between organs.
Among the most relevant mtDNA variants is m.3243A>G in the MT-TL1 gene, classically associated with MELAS, but capable of producing very different phenotypes, including diabetes, deafness, myopathy, stroke-like episodes, renal disease, short stature and hypertrophic or dilated cardiomyopathy. The m.8344A>G variant, associated with MERRF, may be accompanied by myoclonus, epilepsy, ataxia, ragged-red fibers and cardiac involvement. Single large-scale mtDNA deletions are typical of Kearns-Sayre syndrome and chronic progressive external ophthalmoplegia, with a particular risk of atrioventricular conduction defects and sudden death. The same genetic architecture therefore explains why a cardiologist may encounter the disease as ventricular hypertrophy, atrioventricular block, arrhythmia, heart failure or sudden death in a patient with apparently marginal neurological signs.
Nuclear variants include genes involved in mtDNA maintenance, such as POLG, TWNK, SLC25A4, TK2, RRM2B and DNA2; genes involved in mitochondrial translation, such as certain aminoacyl-tRNA synthetase genes; structural or assembly genes of the respiratory chain; genes involved in mitochondrial dynamics, such as OPA1 and MFN2; and genes involved in mitochondrial lipid metabolism, such as TAZ in Barth syndrome. Some variants produce severe infantile disease with early cardiomyopathy, hypotonia, lactic acidosis and multiorgan failure; others generate adult phenotypes with muscle weakness, neuropathy, ophthalmoplegia, progressive cardiomyopathy or conduction disorders. Age at onset alone is therefore not sufficient to distinguish a mitochondrial form from other genetic cardiomyopathies.
The pathophysiological core is defective oxidative phosphorylation. In normal mitochondria, electrons derived from the metabolism of fatty acids, glucose, lactate and ketone bodies pass through the respiratory chain complexes, generate a proton gradient and allow adenosine triphosphate synthase to produce ATP. In the cardiomyocyte, this production supports the actin-myosin cycle, calcium reuptake into the sarcoplasmic reticulum, operation of membrane ion pumps, the action potential, contraction and relaxation. When one or more respiratory complexes function inefficiently, the cardiomyocyte produces less ATP, uses substrates less effectively, increases dependence on glycolysis, accumulates metabolic intermediates and loses energy reserve under stress.
Reduced ATP impairs intracellular calcium handling. The sarcoplasmic reticulum pump, ion exchangers and membrane ATPases require constant energy. If energy is insufficient, cytosolic calcium remains higher, relaxation becomes slower, diastole worsens and contraction becomes inefficient. Altered calcium handling also favors arrhythmias, because it modifies action potential duration, afterdepolarizations and automaticity. This explains why hypertrophy, diastolic dysfunction, tachyarrhythmias, conduction blocks and heart failure may coexist in mitochondrial patients.
The second mechanism is oxidative stress. A defective respiratory chain leaks electrons and increases the formation of reactive oxygen species. In moderate amounts, reactive species participate in cellular signaling; in excess, they oxidize lipids, proteins and DNA, damage mitochondrial membranes, alter respiratory chain enzymes and further amplify energy dysfunction. Cardiolipin, a phospholipid of the inner mitochondrial membrane, is particularly important because it stabilizes respiratory complexes and cristae architecture. In Barth syndrome, tafazzin deficiency alters cardiolipin remodeling, destabilizes the inner mitochondrial membrane and predisposes to dilated cardiomyopathy, left ventricular noncompaction, neutropenia and skeletal myopathy.
The third mechanism is adaptive cardiomyocyte remodeling. When energy production is chronically insufficient, the myocardium may increase cell mass to reduce wall stress and maintain output. This produces a hypertrophic phenotype that may mimic sarcomeric hypertrophic cardiomyopathy. However, mitochondrial hypertrophy is not merely an orderly increase in sarcomeres: it may be accompanied by abnormal mitochondrial proliferation, vacuolization, cristae disorganization, accumulation of subsarcolemmal mitochondria, interstitial fibrosis and reduced contractile efficiency. Over time, the hypertrophic phase may evolve toward dilation and systolic dysfunction, especially if the energy defect is severe or if metabolic crises, arrhythmias, infections or hemodynamic overload are added.
The fourth mechanism concerns conduction. The cardiac conduction system has high energy dependence and requires integrity of membranes, ion pumps and channels. Mitochondrial diseases may produce fascicular blocks, bundle branch block, progressive atrioventricular block, sinus node disease, corrected QT (QTc) prolongation, ventricular tachycardias and atrial fibrillation. In Kearns-Sayre syndrome, conduction system damage is particularly feared because it may rapidly progress to complete atrioventricular block and sudden death. In some forms, sudden death may result not only from bradyarrhythmias, but also from ventricular arrhythmias favored by fibrosis, altered calcium handling and mitochondrial electrical instability.
The fifth mechanism is vulnerability to metabolic crises. Fever, fasting, vomiting, dehydration, anesthesia, surgery, infections, pregnancy, excessive exercise and some medications may exceed the patient’s energy reserve. During a crisis, an already energetically fragile myocardium may deteriorate rapidly, with lactic acidosis, acute heart failure, arrhythmias, hypotension or multiorgan failure. Pathophysiology is therefore dynamic: measuring cardiac function under basal conditions is not sufficient, because risk often emerges when energy demand increases or when substrate availability decreases.
The interaction between the heart and other organs conditions the disease. Skeletal myopathy reduces exercise capacity and may mask cardiac dyspnea; respiratory disease or weakness of ventilatory muscles increases the cardiopulmonary load; nephropathy alters volume, electrolytes and blood pressure; mitochondrial diabetes modifies energy metabolism and vascular risk; deafness and autonomic neuropathy may delay recognition of symptoms; stroke-like neurological episodes may produce systemic stress and instability. For this reason, mitochondrial cardiomyopathy should not be interpreted as a simple rare cardiomyopathy, but as the cardiac manifestation of a multisystemic metabolic network.
The logical sequence of damage may be summarized as follows: an mtDNA or nuclear DNA variant alters a mitochondrial protein, the respiratory chain or the inner mitochondrial membrane; ATP production becomes insufficient or inefficient; the cardiomyocyte loses energy reserve, handles calcium and membrane potential less effectively, increases oxidative stress and activates adaptive responses; the myocardium develops hypertrophy, dilation, fibrosis, diastolic or systolic dysfunction; the conduction system becomes unstable; metabolic stresses precipitate heart failure and arrhythmias. Clinical disease therefore arises from the sum of bioenergetic deficit, structural damage, electrical instability and systemic involvement.
The clinical presentation of mitochondrial cardiomyopathies must be reconstructed starting from a broader history than the one used for an isolated cardiomyopathy. The patient may come to the cardiologist for dyspnea, palpitations, syncope, ventricular hypertrophy, heart failure, atrioventricular block, arrhythmia or family history; but may also be referred by neurology, genetics, pediatrics, nephrology, endocrinology or otolaryngology because a mitochondrial disease is already suspected. The most frequent error is to look only at the ventricle and fail to search for extracardiac signs that make the diagnosis coherent.
The history should investigate disproportionate exercise intolerance, early fatigability, myalgia, cramps, episodes of rhabdomyolysis, ptosis, ophthalmoplegia, diplopia, sensorineural hearing loss, migraine, epileptic seizures, stroke-like neurological episodes, ataxia, neuropathy, cognitive impairment, non-autoimmune diabetes, short stature, growth delay, cyclic vomiting, gastrointestinal dysmotility, dysphagia, liver disease, renal tubulopathy, proteinuria, pigmentary retinopathy, lactic acidosis, recurrent infections, neutropenia, history of metabolic crises and worsening after fasting or fever. Family history should investigate maternal transmission, sudden deaths, pacemaker implantation at a young age, non-ischemic heart failure, deafness, diabetes, epilepsy, juvenile stroke, myopathy or unexplained diagnoses.
The most common cardiac phenotype is left ventricular hypertrophy. It may be concentric, asymmetric, apical or associated with a normal or reduced cavity. The presentation may mimic sarcomeric hypertrophic cardiomyopathy, hypertensive hypertrophy, Fabry disease, amyloidosis or infiltrative heart disease. The difference is that in mitochondrial disease, hypertrophy is often part of a multisystemic picture, may be associated with early diastolic dysfunction, conduction abnormalities, LGE on cardiac magnetic resonance (CMR), elevated lactate, mitochondrial diabetes, deafness or neurological signs. The mere presence of hypertrophy does not identify the cause: it is the clinical context that makes a mitochondrial origin suspicious.
Dilated cardiomyopathy may appear as the initial phenotype or as the evolution of a hypertrophic phase. The patient reports exertional dyspnea, orthopnea, dependent edema, reduced exercise tolerance, asthenia, palpitations and, in advanced cases, hypotension, oliguria and weight loss. In children it may present with feeding difficulty, sweating during feeding, poor growth, tachypnea, recurrent infections and irritability. Ventricular dilation in mitochondrial disease indicates loss of energy compensation and activation of heart failure remodeling, with a more severe prognosis than an isolated morphological finding.
Left ventricular noncompaction may be present in some mitochondrial syndromes, particularly Barth syndrome, but also in other defects of mitochondrial function. On this page it should be interpreted as part of a bioenergetic defect and not as a repetition of autonomous noncompaction cardiomyopathy. The finding may contribute to systolic dysfunction, thrombotic risk and arrhythmias, but the core problem remains mitochondrial impairment of the cardiomyocyte and, when present, the associated systemic disease.
Conduction disorders are a crucial manifestation. The patient may be asymptomatic or may report presyncope, syncope, dizziness, sudden asthenia, slow palpitations, exercise intolerance or episodes of loss of consciousness. The electrocardiogram (ECG) may show first-degree atrioventricular block, advanced atrioventricular block, fascicular blocks, bundle branch block, sinus node disease, pre-excitation or repolarization abnormalities. In Kearns-Sayre syndrome, the onset of conduction disorders is a high-risk signal, because progression may be rapid and sudden death may precede a long cardiological history.
Arrhythmias may be supraventricular or ventricular. Atrial fibrillation may result from atrial dilation, increased filling pressures, hypertrophy, fibrosis or autonomic dysfunction. Ventricular tachycardias may emerge in the presence of fibrosis, dilated cardiomyopathy, systolic dysfunction, calcium abnormalities or high-risk genotypes. Palpitations in these patients should not be dismissed as a benign symptom, because even an apparently intermittent arrhythmia may represent the first sign of electrical instability in a metabolically fragile heart.
Chest pain is less specific. It may result from microvascular ischemia, hypertrophy with increased energy demand, concomitant coronary artery disease, arrhythmias, acidosis, thoracic myopathy or non-cardiac causes. In patients with mitochondrial disease and acute pain, acute coronary syndrome, myocarditis, pulmonary embolism and aortic dissection must still be excluded according to the clinical presentation. The presence of a mitochondrial diagnosis should not reduce vigilance toward common acute conditions.
Systemic manifestations help recognize the picture. Ptosis and progressive ophthalmoplegia point toward mtDNA defects or Kearns-Sayre syndrome; sensorineural hearing loss and diabetes suggest m.3243A>G; stroke-like episodes with lactic acidosis and epileptic seizures point toward MELAS; myoclonus, ataxia and ragged-red fibers point toward MERRF; neutropenia, skeletal myopathy, reduced growth and early cardiomyopathy point toward Barth syndrome; optic neuropathy may suggest specific variants such as those associated with Leber hereditary optic neuropathy. No sign is exclusive, but the combination of heart, muscle, brain, eye, ear and endocrine system is highly suggestive.
Physical examination starts from vital signs and cardiac assessment, but must continue with a multisystemic examination. Cardiovascular evaluation searches for murmurs, third heart sound, irregular rhythm, jugular venous distension, crackles, hepatomegaly, edema, signs of hypoperfusion and blood pressure. Neurological evaluation observes ptosis, ophthalmoplegia, nystagmus, ataxia, muscle strength, reflexes, neuropathy and coordination. Muscular evaluation assesses hypotrophy, proximal weakness, fatigability and posture. In pediatrics, growth, nutrition, hypotonia, psychomotor development and infections are considered. The heart is a target organ, but the visit must search for the systemic pattern that makes the diagnosis plausible.
A relevant clinical feature is the disproportion between symptoms and cardiac findings. A patient may appear very fatigued because of skeletal myopathy even with preserved ventricular function; conversely, they may have significant hypertrophy or conduction blocks with few symptoms because physical activity is already limited by muscle weakness or neuropathy. For this reason, functional assessment must integrate cardiology, neurology and metabolism, avoiding attribution of the entire reduction in exertion to the heart or, conversely, underestimating the heart because the patient is “only myopathic”.
The diagnosis of mitochondrial cardiomyopathy requires an integrated approach. There is no single cardiological test capable of confirming on its own the mitochondrial nature of the cardiomyopathy. Echocardiography may show hypertrophy, dilation, noncompaction or dysfunction; CMR may show fibrosis or suggestive patterns; ECG may document blocks or arrhythmias; lactate may be elevated; muscle biopsy may show histological abnormalities; genetic testing may identify a pathogenic variant. The diagnosis arises from the convergence of cardiac phenotype, systemic signs, biochemistry, genetics and, when necessary, histology.
The first level in a patient with suspected mitochondrial disease and possible cardiac involvement includes personal and family history, cardiological and neurological examination, 12-lead ECG, transthoracic echocardiography, Holter ECG, troponin if the presentation is acute, B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) if symptoms of heart failure are present, electrolytes, creatinine, glucose, glycated hemoglobin, liver function, creatine kinase, lactate, pyruvate when appropriate, thyroid function and audiological, ophthalmological, neurological or nephrological evaluation according to the clinical picture. Normal lactate does not exclude the disease; elevated lactate must be interpreted cautiously because it may increase after difficult blood sampling, hypoperfusion, seizures, exercise, sepsis or liver failure.
The ECG is essential because conduction defects may precede ventricular dysfunction. One must look for atrioventricular block, fascicular blocks, bundle branch block, pre-excitation, long QTc, pseudoinfarction Q waves, signs of hypertrophy, repolarization abnormalities and abnormal atrial rhythm. Holter ECG or prolonged monitoring is useful to detect pauses, non-sustained ventricular tachycardia, atrial fibrillation, frequent extrasystoles or intermittent blocks. In patients with syncope, unexplained palpitations, Kearns-Sayre syndrome, m.3243A>G or suspected electrical risk, monitoring should be more aggressive than in a stable cardiomyopathy without red flags.
Echocardiography defines the phenotype. It must measure wall thicknesses, ventricular mass, ventricular dimensions, left ventricular ejection fraction (LVEF), diastolic function, right ventricular function, atria, valves, estimated pulmonary pressure, presence of trabeculation, intracavitary thrombi and global longitudinal strain (GLS) when available. In hypertrophic forms, mitochondrial hypertrophy must be distinguished from hypertension, sarcomeric hypertrophic cardiomyopathy, Fabry disease, amyloidosis and storage heart diseases. In dilated forms, it is necessary to assess whether the pattern is compatible with non-ischemic cardiomyopathy, myocarditis, toxicity, tachycardiomyopathy or overlapping genetic disease.
CMR is central in morphological and tissue characterization. It allows precise measurement of volumes, mass, LVEF, right ventricular function, trabeculation, edema, fibrosis and late gadolinium enhancement (LGE) pattern. In patients with mitochondrial disease, it may show ventricular hypertrophy, focal or diffuse LGE, strain abnormalities, ventricular remodeling and, in some cases, findings that help distinguish the disease from other causes of hypertrophy. T1 mapping, extracellular volume and T2 mapping may provide information on diffuse fibrosis, edema or tissue abnormalities not visible with traditional sequences alone. CMR is particularly useful when echocardiography and clinical findings do not explain symptom severity or when the differential diagnosis with hypertrophic cardiomyopathy, Fabry disease, amyloidosis or myocarditis remains open.
Genetic diagnosis requires combined analysis of mtDNA and nuclear genes. In suspected mitochondrial disease, a conventional cardiomyopathy panel analyzing only sarcomeric or cytoskeletal genes is not sufficient. It is necessary to include the mitochondrial genome, the search for point variants, mtDNA deletions, multiple deletions, maintenance defects and relevant nuclear mitochondrial genes. The choice of sample is important: blood, urine, fibroblasts, muscle or other tissues may have different sensitivity depending on the variant and heteroplasmy. In some mtDNA variants, blood may become falsely less informative with age, while urinary sediment or muscle may retain a higher mutational load.
In the absence of uniform official cardiological diagnostic criteria, according to the standards of care of the Mitochondrial Medicine Society and the approach of the ESC guidelines on cardiomyopathies, diagnosing mitochondrial cardiomyopathy requires coherent integration of the following elements:
elements required for a clinically grounded diagnosis
Muscle biopsy has lost its role as the sole pivotal test thanks to next-generation genetics, but remains useful in selected cases. It may show ragged-red fibers, cytochrome c oxidase-negative fibers, subsarcolemmal mitochondrial accumulation, ultrastructural abnormalities, respiratory complex deficiencies or enzymatic abnormalities. However, a normal muscle biopsy does not exclude all mitochondrial diseases, especially if the sampled tissue is not the most involved or if the defect is heterogeneously expressed. Endomyocardial biopsy is rarely necessary, but may be considered when cardiac suspicion is strong and other assessments are not conclusive, or when it is necessary to distinguish the condition from myocarditis, infiltration, storage disease or another treatable cardiomyopathy.
The differential diagnosis must be systematic. Sarcomeric hypertrophic cardiomyopathy may mimic mitochondrial hypertrophy, but usually does not present the same multisystemic pattern. Fabry disease may cause hypertrophy, neuropathic pain, proteinuria, angiokeratomas and inferolateral LGE; it must be sought because it has specific enzyme replacement or chaperone therapy. Amyloidosis may cause apparent hypertrophy, low voltages, neuropathy, proteinuria and a characteristic CMR pattern. Hypertensive heart disease must be distinguished based on blood pressure history, regression, hypertrophy pattern and organ damage. Myocarditis may produce pain, elevated troponin, dysfunction and LGE. Anthracycline toxicity, alcohol, tachycardiomyopathy, ischemia and endocrinopathies must be excluded when coherent with the picture.
Family evaluation depends on the genetic defect. In mtDNA variants, reconstructing the maternal line is essential, because transmission is maternal and clinical expression varies because of heteroplasmy and replicative segregation. In nuclear variants, screening follows the specific inheritance model. Genetic counseling must address reproductive risk, the possibility of prenatal or preimplantation diagnosis, the limits of heteroplasmy, variants of uncertain significance and the need for clinical follow-up even in paucisymptomatic carriers. Genetic diagnosis does not only serve to name the disease, but to guide cardiac, neurological, renal, endocrine and family surveillance.
Diagnostic follow-up does not end with the first visit. Cardiac involvement may appear after years in an already diagnosed mitochondrial patient, or may progress from mild hypertrophy to dysfunction, from first-degree block to advanced block, from sporadic palpitations to major arrhythmias. For this reason, periodic checks with ECG, echocardiography and rhythm monitoring are needed, modulated according to genotype, age, symptoms, CMR, family history and event history. Surveillance must be closer in patients with Kearns-Sayre syndrome, m.3243A>G, ventricular dysfunction, LGE, conduction disorders or documented arrhythmias.
The treatment of mitochondrial cardiomyopathies is complex because in most cases there is no therapy capable of directly correcting the underlying genetic defect. Management is based on four levels: cardiological treatment of the phenotype, prevention of metabolic crises, multisystemic care of mitochondrial disease and family surveillance. Treatment must be personalized because a patient with stable hypertrophy and conduction block does not require the same strategy as a child with Barth syndrome and heart failure, an adult with MELAS and hypertrophic cardiomyopathy, or a patient with Kearns-Sayre syndrome and progressive atrioventricular block.
When heart failure with reduced LVEF is present, validated heart failure therapies are applied, adapted to the patient’s tolerance. Angiotensin receptor neprilysin inhibitor (ARNI), ACE inhibitor, angiotensin receptor blocker, beta-blocker, mineralocorticoid receptor antagonist (MRA), sodium-glucose cotransporter 2 inhibitor (SGLT2 inhibitor) and diuretics may be used when congestion is present. Titration must consider blood pressure, renal function, nutritional status, dysautonomia, risk of dehydration and metabolic crises. In patients with severe myopathy, low body weight or multisystemic disease, standard doses may not be tolerated and may require slower progression.
In hypertrophic forms with preserved systolic function, treatment depends on symptoms, outflow tract obstruction, diastolic dysfunction, arrhythmias and differential diagnosis. If there is no significant obstruction, management aims to control heart rate, blood pressure, congestion, arrhythmias and comorbidities. If dynamic obstruction is present, treatment follows principles similar to those of obstructive hypertrophic cardiomyopathy, but with additional caution linked to metabolic fragility. Therapy should not be chosen based only on wall thickness: it is necessary to understand whether hypertrophy is compensatory, infiltrative, sarcomeric, mitochondrial or mixed.
Conduction disorders require surveillance and early intervention. In high-risk syndromes, such as Kearns-Sayre syndrome, fascicular blocks, bundle branch block, prolonged PR interval or syncope must be considered important signals. A pacemaker may be indicated before complete atrioventricular block appears if the risk of progression is high. In some patients, especially if ventricular dysfunction, tachyarrhythmias, LGE, family history or arrhythmic events coexist, it must be considered whether an implantable cardioverter-defibrillator (ICD) is more appropriate than a pacemaker alone. The decision must be specialist-led, because risk may include both bradyarrhythmias and ventricular arrhythmias.
Ventricular arrhythmias and prevention of sudden death follow general recommendations for cardiomyopathies and arrhythmias, but with attention to genotype and systemic context. The ICD is indicated for secondary prevention after cardiac arrest or non-reversible sustained ventricular tachycardia. In primary prevention, the decision integrates LVEF, LGE, syncope, non-sustained ventricular tachycardia, family history, conduction disorders and the type of mitochondrial disease. Antiarrhythmics must be chosen cautiously, considering liver function, renal function, interactions, QTc prolongation and possible mitochondrial effects. Correction of electrolytes, fever, hypoxia, acidosis and dehydration is part of arrhythmic control.
Prevention of metabolic crises is part of cardiological treatment. The patient must avoid prolonged fasting, dehydration, uncontrolled excessive exercise and delays in treating fever and infections, and must receive appropriate perioperative protocols. During acute illness, glucose supply, controlled hydration, correction of acidosis, cardiac monitoring, electrolyte control and intensive management may be required if heart failure appears. The aim is not only to protect general metabolism, but to prevent a heart with low energy reserve from being pushed beyond the threshold of compensation.
Pharmacological management requires attention to medications that may be problematic in mitochondrial diseases. Valproate must be avoided especially in POLG-related diseases because of the risk of severe hepatotoxicity. Aminoglycosides may be particularly dangerous in specific mitochondrial variants predisposing to deafness. Some anesthetics, antiepileptics, antiretrovirals, chemotherapeutics, statins or medications that interfere with energy metabolism, conduction or QTc require individual assessment. This does not mean indiscriminately prohibiting entire classes, but using conscious prescribing, real indication, monitoring and coordination among specialists.
Metabolic supplementation is frequently used, but evidence of efficacy is heterogeneous. Coenzyme Q10, riboflavin, L-carnitine, creatine, thiamine, alpha-lipoic acid, arginine or citrulline in specific contexts may be considered in expert centers, but they do not replace cardiological therapy, arrhythmic surveillance and management of complications. In forms due to primary coenzyme Q10 deficiency, supplementation may have a stronger specific rationale. In stroke-like episodes associated with MELAS, arginine or citrulline have been proposed in specialist protocols. Metabolic therapy should therefore be targeted to the defect or syndrome, not applied as a generic formula.
Treatment of specific diseases must follow the phenotype. In Barth syndrome, heart failure management, arrhythmia surveillance, neutropenia control, infection prevention, nutritional support, growth assessment and genetic follow-up are needed. In Kearns-Sayre syndrome, the focus is conduction surveillance and timely device implantation when indicated. In patients with m.3243A>G, the heart, diabetes, kidneys, hearing, neurology and risk of stroke-like episodes must be monitored. In POLG-related diseases, valproate must be avoided and liver, neurology and heart must be monitored. This subtype-based medicine is essential because “mitochondrial” is not a sufficient therapeutic diagnosis.
Physical activity should be prescribed prudently but not automatically prohibited. Moderate, supervised and adapted aerobic exercise may improve functional capacity and quality of life in some mitochondrial myopathies, while maximal exertion, fasting, dehydration and non-calibrated training may precipitate symptoms or crises. In patients with arrhythmias, reduced LVEF, LGE, syncope or severe cardiomyopathy, cardiological evaluation must precede any program. The goal is to avoid both harmful immobility and exposure to unsustainable energy loads.
Pregnancy requires preconception counseling. In women with mtDNA variants, there are implications of maternal transmission and variability of heteroplasmy in the offspring. From a cardiological perspective, risk depends on LVEF, hypertrophy, arrhythmias, conduction, renal function, diabetes, nutritional status and neurological disease. Pregnancy increases plasma volume, cardiac output and energy demand, so it may unmask or worsen a cardiac phenotype. Management must be multidisciplinary, including cardiology, genetics, high-risk obstetrics, neurology and metabolism.
In advanced cases, ventricular assistance or heart transplantation may become necessary, but selection is more complex than in other cardiomyopathies. Transplantation may be considered when extracardiac disease is limited and systemic prognosis is compatible, but may be precluded or made risky by severe myopathy, progressive neurological disease, renal failure, malnutrition, infections, complex diabetes or stroke-like episodes. In patients with MELAS m.3243A>G, for example, neurological, renal and nutritional risk may hinder the transplant pathway. The decision must be made in expert centers, with integrated cardiological and metabolic assessment.
Prognosis is extremely variable. Favorable factors include early diagnosis, preserved ventricular function, absence of LGE, absence of major arrhythmias, stability of the conduction system, low extracardiac involvement and the possibility of preventing metabolic crises. Unfavorable factors include severe neonatal or infantile onset, dilated cardiomyopathy, reduced LVEF, fibrosis on CMR, progressive conduction block, ventricular arrhythmias, renal failure, malnutrition, respiratory weakness, stroke-like neurological episodes, recurrent lactic acidosis and genetic variants with severe multisystemic phenotype. Cardiac prognosis cannot be separated from overall metabolic prognosis.
The complications of mitochondrial cardiomyopathies result from the interaction between cardiomyocyte energy deficit, electrical instability, structural progression, metabolic crises and multisystemic involvement. Unlike other cardiomyopathies, the heart may worsen not only because of intrinsic remodeling, but also during fever, fasting, anesthesia, infections, vomiting, dehydration, epileptic seizures, surgery or metabolic decompensation. Prevention of complications therefore requires cardiological surveillance and the ability to anticipate systemic stresses.
Heart failure is a central complication. In hypertrophic forms it may begin as diastolic dysfunction, with increased filling pressures, dyspnea, exercise intolerance and congestion. In dilated forms, reduced LVEF, ventricular dilation, functional mitral regurgitation, low output and hospitalizations appear. Deterioration may be gradual or acute during metabolic crises. ATP loss reduces contractility and relaxation, while fibrosis, oxidative stress and neurohormonal activation stabilize the damage. Mitochondrial heart failure is therefore an energy failure before being a mechanical one.
Arrhythmias are a frequent and potentially fatal complication. Atrial fibrillation, atrial flutter, non-sustained ventricular tachycardia, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes and bradyarrhythmias may occur. The substrate consists of fibrosis, altered calcium handling, membrane instability, conduction defects and reduced energy reserve. Arrhythmias may rapidly worsen heart failure because a heart with low mitochondrial reserve poorly tolerates tachycardia, loss of atrial systole, rhythm irregularity and hypotension.
Conduction defects are particularly important in mtDNA deletion syndromes and in Kearns-Sayre syndrome. They may begin with fascicular blocks or first-degree atrioventricular block and progress to advanced or complete block. The most feared complication is syncope or sudden death due to pause, asystole or associated ventricular arrhythmia. Since progression may be rapid, a mildly abnormal ECG in a patient with a mitochondrial phenotype should not be considered a trivial finding.
Sudden death may result from complete atrioventricular block, ventricular tachycardia, ventricular fibrillation, torsades de pointes, severe dysfunction or a combination of bradyarrhythmia and ventricular instability. Sudden events have been described in carriers of m.3243A>G even in apparently mildly symptomatic adults; in syndromes with progressive conduction disease, risk is linked to vulnerability of the electrical system. Prevention requires serial screening, rhythm monitoring, timely device implantation when indicated and attention to medications that prolong QTc or worsen conduction.
Progression from hypertrophy to dilation is a significant structural complication. Initially, hypertrophy may compensate for reduced energy efficiency by increasing mass and apparent contractile capacity; over time, accumulation of oxidative damage, fibrosis, metabolic crises and loss of cardiomyocytes may transform the phenotype into dilated cardiomyopathy. This transition worsens prognosis, increases arrhythmic risk, favors thrombosis and may lead to advanced heart failure.
Myocardial fibrosis is both a complication and a prognostic marker. It results from chronic cardiomyocyte damage, oxidative stress, low-grade inflammation, remodeling and tissue repair. On CMR it may appear as focal or diffuse LGE, sometimes with a non-ischemic pattern. Fibrosis reduces elasticity, worsens filling, hinders uniform conduction and creates a substrate for arrhythmias. Its presence must increase the level of surveillance even when LVEF is not yet severely reduced.
Thromboembolic complications may occur if atrial fibrillation, ventricular dysfunction, dilation, noncompaction, intracavitary thrombus or immobility coexist. Risk does not derive from mitochondrial disease in the abstract, but from conditions that favor stasis and arrhythmias. A stroke in a mitochondrial patient may be cardioembolic or may be a metabolic stroke-like episode, especially in MELAS syndromes. The distinction is essential because it changes treatment, prevention and prognostic interpretation.
Metabolic crises are systemic complications with direct cardiac impact. During fever, fasting or infection, the patient may develop lactic acidosis, hypoglycemia, dehydration, electrolyte imbalances and catabolism. The heart responds with tachycardia, increased energy consumption, worsening contractility and arrhythmic risk. In children and patients with severe disease, a metabolic crisis may precipitate acute heart failure or multiorgan failure. Prevention of crises is therefore a cardioprotective measure.
Respiratory complications aggravate the heart. Weakness of respiratory muscles, recurrent infections, aspiration, nocturnal hypoventilation and respiratory failure increase hypoxia, hypercapnia and right ventricular load. Hypoxia worsens mitochondrial function and increases arrhythmic risk. In patients with severe skeletal myopathy, respiratory evaluation is part of cardiological prevention, because inadequate ventilation may be the factor that precipitates heart failure.
Renal and endocrine complications modify cardiac management. Nephropathy, tubulopathy and renal failure alter volume, potassium, magnesium, acidity and tolerance of heart failure medications. Mitochondrial diabetes may increase metabolic vulnerability, infection risk and vascular complications. Thyroid or adrenal abnormalities, when present, may modify heart rate, blood pressure and metabolism. Cardiological treatment must therefore be recalibrated according to the organs involved, not applied as a fixed scheme.
Iatrogenic complications are particularly relevant. Prolonged perioperative fasting, inadequate hydration, unnecessary medications that interfere with mitochondrial metabolism, unplanned anesthesia, failure to monitor rhythm in patients with unstable conduction or insufficient correction of electrolytes may precipitate preventable events. Prevention requires that the mitochondrial diagnosis be clearly communicated in surgical, anesthesiological, neurological and emergency pathways.
Family and reproductive complications are not biological complications of the heart, but clinical consequences of the diagnosis. An mtDNA variant may involve relatives along the maternal line with very different severity; a nuclear variant may imply risk for siblings, children or other relatives. Failure to recognize the hereditary nature may leave individuals at risk of conduction blocks, heart failure or sudden death without surveillance. Genetic counseling is therefore part of complication prevention, not an administrative step.
The most dangerous complication in practical terms is fragmentation of care. If the patient is followed only as a cardiomyopathy, metabolic crises, neurology, nephropathy, diabetes, deafness or anesthetic risk may be ignored. If the patient is followed only as a neurological disease, conduction, arrhythmias and fibrosis may be ignored. Effective management requires a multidisciplinary model in which cardiology, genetics, neurology, metabolism, nephrology, endocrinology, anesthesia and pediatrics or internal medicine share information and intervention thresholds.